雌激素受体阳性乳腺癌及其内在机制:乳腺癌对传统药物和相关疗法的耐药性综述。

IF 4.5 3区 生物学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Open Biology Pub Date : 2024-06-01 Epub Date: 2024-06-19 DOI:10.1098/rsob.230272
Manu Yadav, Ishita Vaishkiar, Ananya Sharma, Akanksha Shukla, Aradhana Mohan, Madhuri Girdhar, Anil Kumar, Tabarak Malik, Anand Mohan
{"title":"雌激素受体阳性乳腺癌及其内在机制:乳腺癌对传统药物和相关疗法的耐药性综述。","authors":"Manu Yadav, Ishita Vaishkiar, Ananya Sharma, Akanksha Shukla, Aradhana Mohan, Madhuri Girdhar, Anil Kumar, Tabarak Malik, Anand Mohan","doi":"10.1098/rsob.230272","DOIUrl":null,"url":null,"abstract":"<p><p>Traditional medication and alternative therapies have long been used to treat breast cancer. One of the main problems with current treatments is that there is an increase in drug resistance in the cancer cells owing to genetic differences such as mutational changes, epigenetic changes and miRNA (microRNA) alterations such as miR-1246, miR-298, miR-27b and miR-33a, along with epigenetic modifications, such as Histone3 acetylation and CCCTC-Binding Factor (CTCF) hypermethylation for drug resistance in breast cancer cell lines. Certain forms of conventional drug resistance have been linked to genetic changes in genes such as <i>ABCB1</i>, <i>AKT</i>, <i>S100A8/A9</i>, <i>TAGLN2</i> and <i>NPM</i>. This review aims to explore the current approaches to counter breast cancer, the action mechanism, along with novel therapeutic methods endowing potential drug resistance. The investigation of novel therapeutic approaches sheds light on the phenomenon of drug resistance including genetic variations that impact distinct forms of oestrogen receptor (ER) cancer, genetic changes, epigenetics-reported resistance and their identification in patients. Long-term effective therapy for breast cancer includes selective oestrogen receptor modulators, selective oestrogen receptor degraders and genetic variations, such as mutations in nuclear genes, epigenetic modifications and miRNA alterations in target proteins. Novel research addressing combinational therapies including maytansine, photodynamic therapy, guajadiol, talazoparib, COX2 inhibitors and miRNA 1246 inhibitors have been developed to improve patient survival rates.</p>","PeriodicalId":19629,"journal":{"name":"Open Biology","volume":"14 6","pages":"230272"},"PeriodicalIF":4.5000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285512/pdf/","citationCount":"0","resultStr":"{\"title\":\"Oestrogen receptor positive breast cancer and its embedded mechanism: breast cancer resistance to conventional drugs and related therapies, a review.\",\"authors\":\"Manu Yadav, Ishita Vaishkiar, Ananya Sharma, Akanksha Shukla, Aradhana Mohan, Madhuri Girdhar, Anil Kumar, Tabarak Malik, Anand Mohan\",\"doi\":\"10.1098/rsob.230272\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Traditional medication and alternative therapies have long been used to treat breast cancer. One of the main problems with current treatments is that there is an increase in drug resistance in the cancer cells owing to genetic differences such as mutational changes, epigenetic changes and miRNA (microRNA) alterations such as miR-1246, miR-298, miR-27b and miR-33a, along with epigenetic modifications, such as Histone3 acetylation and CCCTC-Binding Factor (CTCF) hypermethylation for drug resistance in breast cancer cell lines. Certain forms of conventional drug resistance have been linked to genetic changes in genes such as <i>ABCB1</i>, <i>AKT</i>, <i>S100A8/A9</i>, <i>TAGLN2</i> and <i>NPM</i>. This review aims to explore the current approaches to counter breast cancer, the action mechanism, along with novel therapeutic methods endowing potential drug resistance. The investigation of novel therapeutic approaches sheds light on the phenomenon of drug resistance including genetic variations that impact distinct forms of oestrogen receptor (ER) cancer, genetic changes, epigenetics-reported resistance and their identification in patients. Long-term effective therapy for breast cancer includes selective oestrogen receptor modulators, selective oestrogen receptor degraders and genetic variations, such as mutations in nuclear genes, epigenetic modifications and miRNA alterations in target proteins. Novel research addressing combinational therapies including maytansine, photodynamic therapy, guajadiol, talazoparib, COX2 inhibitors and miRNA 1246 inhibitors have been developed to improve patient survival rates.</p>\",\"PeriodicalId\":19629,\"journal\":{\"name\":\"Open Biology\",\"volume\":\"14 6\",\"pages\":\"230272\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285512/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Biology\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1098/rsob.230272\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Biology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1098/rsob.230272","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

长期以来,传统药物和替代疗法一直被用于治疗乳腺癌。目前治疗方法的主要问题之一是,由于基因差异,如突变、表观遗传变化和 miRNA(microRNA)改变,如 miR-1246、miR-298、miR-27b 和 miR-33a,以及表观遗传修饰,如组蛋白 3 乙酰化和 CCCTC 结合因子(CTCF)超甲基化,导致乳腺癌细胞株耐药性增加。某些形式的常规耐药性与 ABCB1、AKT、S100A8/A9、TAGLN2 和 NPM 等基因的遗传变化有关。这篇综述旨在探讨目前对抗乳腺癌的方法、作用机制以及具有潜在耐药性的新型治疗方法。对新型治疗方法的研究揭示了耐药性现象,包括影响不同形式雌激素受体(ER)癌的基因变异、基因变化、表观遗传学报告的耐药性及其在患者中的识别。乳腺癌的长期有效疗法包括选择性雌激素受体调节剂、选择性雌激素受体降解剂和基因变异,如核基因突变、表观遗传修饰和靶蛋白中 miRNA 的改变。为提高患者的生存率,已开发出针对组合疗法的新型研究,包括美坦素、光动力疗法、瓜加地尔、talazoparib、COX2 抑制剂和 miRNA 1246 抑制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Oestrogen receptor positive breast cancer and its embedded mechanism: breast cancer resistance to conventional drugs and related therapies, a review.

Traditional medication and alternative therapies have long been used to treat breast cancer. One of the main problems with current treatments is that there is an increase in drug resistance in the cancer cells owing to genetic differences such as mutational changes, epigenetic changes and miRNA (microRNA) alterations such as miR-1246, miR-298, miR-27b and miR-33a, along with epigenetic modifications, such as Histone3 acetylation and CCCTC-Binding Factor (CTCF) hypermethylation for drug resistance in breast cancer cell lines. Certain forms of conventional drug resistance have been linked to genetic changes in genes such as ABCB1, AKT, S100A8/A9, TAGLN2 and NPM. This review aims to explore the current approaches to counter breast cancer, the action mechanism, along with novel therapeutic methods endowing potential drug resistance. The investigation of novel therapeutic approaches sheds light on the phenomenon of drug resistance including genetic variations that impact distinct forms of oestrogen receptor (ER) cancer, genetic changes, epigenetics-reported resistance and their identification in patients. Long-term effective therapy for breast cancer includes selective oestrogen receptor modulators, selective oestrogen receptor degraders and genetic variations, such as mutations in nuclear genes, epigenetic modifications and miRNA alterations in target proteins. Novel research addressing combinational therapies including maytansine, photodynamic therapy, guajadiol, talazoparib, COX2 inhibitors and miRNA 1246 inhibitors have been developed to improve patient survival rates.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Open Biology
Open Biology BIOCHEMISTRY & MOLECULAR BIOLOGY-
CiteScore
10.00
自引率
1.70%
发文量
136
审稿时长
6-12 weeks
期刊介绍: Open Biology is an online journal that welcomes original, high impact research in cell and developmental biology, molecular and structural biology, biochemistry, neuroscience, immunology, microbiology and genetics.
期刊最新文献
Axon demyelination and degeneration in a zebrafish spastizin model of hereditary spastic paraplegia. Cebpa is required for haematopoietic stem and progenitor cell generation and maintenance in zebrafish. SID-2 is a conserved extracellular vesicle protein that is not associated with environmental RNAi in parasitic nematodes. Mathematical model of RNA-directed DNA methylation predicts tuning of negative feedback required for stable maintenance. Learning-induced remodelling of inhibitory synapses in the motor cortex.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1